Key stats
About VanEck Biotech ETF
Home page
Inception date
Dec 20, 2011
Structure
Open-Ended Fund
Dividend treatment
Distributes
Distribution tax treatment
Qualified dividends
Income tax type
Capital Gains
Max ST capital gains rate
39.60%
Max LT capital gains rate
20.00%
Primary advisor
Van Eck Associates Corp.
Distributor
Van Eck Securities Corp.
BBH offers a more concentrated take on the global biotech industry. Although the space is already dominated by US firms, the fund aims to select just 25 US listed companies by market cap, also weighing each constituent by market cap. The underlying index has a flexible definition of biotech, encompassing companies engaged primarily in research (including research contractors) and development as well as production, marketing and sales of drugs based on genetic analysis and diagnostic equipment, excluding pharmacies. Also, despite capping its issuers to a maximum of 20%, the fund may still be top heavy due to the index’s concentrated nature. Overall, BBH is a viable take on this market. The index is reviewed semi-annually.
Classification
Returns
| 1 month | 3 months | Year to date | 1 year | 3 years | 5 years | |
|---|---|---|---|---|---|---|
| Price performance | — | — | — | — | — | — |
| NAV total return | — | — | — | — | — | — |
What's in the fund
Exposure type
Health Technology
Stocks100.01%
Health Technology95.63%
Commercial Services4.37%
Bonds, Cash & Other−0.01%
Cash−0.01%
Stock breakdown by region
North America84.96%
Europe15.04%
Latin America0.00%
Asia0.00%
Africa0.00%
Middle East0.00%
Oceania0.00%
Top 10 holdings
Dividends
Dividend payout history
Assets under management (AUM)
Fund Flows
Frequently Asked Questions
BBH invests in stocks. The fund's major sectors are Health Technology, with 95.64% stocks, and Commercial Services, with 4.37% of the basket. The assets are mostly located in the North America region.
BBH top holdings are Amgen Inc. and Gilead Sciences, Inc., occupying 16.13% and 13.50% of the portfolio correspondingly.
BBH last dividends amounted to 1.25 USD. The year before, the issuer paid 0.71 USD in dividends, which shows a 43.06% increase.
BBH assets under management is 333.83 M USD. It's fallen 4.55% over the last month.
BBH fund flows account for −65.19 M USD (1 year). Many traders use this metric to get insight into investors' sentiment and evaluate whether it's time to buy or sell the fund.
Yes, BBH pays dividends to its holders with the dividend yield of 0.83%. The last dividend (Dec 24, 2024) amounted to 1.25 USD. The dividends are paid annually.
BBH shares are issued by Van Eck Associates Corp. under the brand VanEck. The ETF was launched on Dec 20, 2011, and its management style is Passive.
BBH expense ratio is 0.35% meaning you'd have to pay 0.35% of your investment to help manage the fund.
BBH follows the MVIS US Listed Biotech 25. ETFs usually track some benchmark seeking to replicate its performance and guide asset selection and objectives.
BBH invests in stocks.
BBH price has fallen by −1.36% over the last month, and its yearly performance shows a −8.82% decrease. See more dynamics on BBH price chart.
NAV returns, another gauge of an ETF dynamics, have fallen by −2.91% over the last month, showed a −9.76% decrease in three-month performance and has decreased by −7.82% in a year.
NAV returns, another gauge of an ETF dynamics, have fallen by −2.91% over the last month, showed a −9.76% decrease in three-month performance and has decreased by −7.82% in a year.
BBH trades at a premium (0.12%) meaning the ETF is trading at a higher price than the calculated NAV.